The opioid growth factor (OGF) – opioid growth factor receptor (OGFr) axis is a biological pathway that is present in human ovarian cancer cells and tissues. OGF, chemically termed [Met5]-enkephalin, is an endogenous opioid peptide that interfaces with OGFr to delay cells moving through the cell cycle by upregulation of cyclin-dependent inhibitory kinase pathways. OGF inhibitory activity is dose dependent, receptor mediated, reversible, protein and RNA dependent, but not related to apoptosis or necrosis. The OGF-OGFr axis can be targeted for treatment of human ovarian cancer by (i) administration of exogenous OGF, (ii) genetic manipulation to over-express OGFr and (iii) use of low dosages of naltrexone, an opioid antagonist, which stimulates production of OGF and OGFr for subsequent interaction following blockade of the receptor. The OGF-OGFr axis may be a feasible target for treatment of cancer of the ovary (i) in a prophylactic fashion, (ii) following cytoreduction or (iii) in conjunction with standard chemotherapy for additive effectiveness. In summary, preclinical data support the transition of these novel therapies for treatment of human ovarian cancer from the bench to bedside to provide additional targets for treatment of this devastating disease.
RomeroIBastRC. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology2012; 153: 1593–602.
2.
LeungPCKChoiJ-H. Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update2007; 13: 143–62.
3.
BastRC. CA125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer2010; 116: 2850–3.
4.
SoslowRA. Histologic subtypes of ovarian carcinomas: an overview. Int J Gynecol Pathol2008; 27: 161–74.
5.
JemalABrayFCenterMMFerlayJWardEFormanD. Global cancer statistics. CA Cancer J Clin2011; 61: 69–90.
6.
Howlander N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhi J, Tatlovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA. (eds). SEER Cancer Statistics Review, 1975-2009, National Cancer Institute, Bethesda, MD. See http://seer.cancer.gov/statfacts.html.ovary.html..
7.
American Cancer Society, Cancer Facts and Figures 2012, Altanta GA: American Cancer Society, 2012.
8.
LynchHTWatsonPLynchJConwayTAFiliM. Hereditary ovarian cancer. Heterogeneity in age at onset. Cancer1993; 71(Suppl 2)573–81.
9.
YancikR. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer1993; 71(Suppl 2)517–23.
10.
PensonRTShannonKESharplessNESeidenMV. Ovarian cancer: an update on genetics and therapy. Compr Ther1998; 24: 477–87.
11.
PiverMSGoldbergJMTsukadaYMettlinCJJishiMFNatarajanN. Characteristics of familial ovarian cancer: a report of the first 1000 families in the Gilda Radner Familial Ovarian Cancer Registry. Eur J Gynaecol Oncol1996; 17: 169–76.
12.
WoosterRNewhausenSLMangionJQuirkYFordDCollinsNNguyenKSealSTranTAverillD. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science1994; 265: 2088–90.
13.
StruewingJPHartgePWacholderSBakerSMBerlinMMcAdamsMTimmermanMMBrodyLCTuckerMA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med1997; 336: 1401–8.
ZagonISMcLaughlinPJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science1983; 221: 671–3.
16.
ZagonISMcLaughlinPJ. Increased brain size and cellular content in infant rats treated with an opiate antagonist. Science1983; 221: 1179–80.
17.
ZagonISMcLaughlinPJ. Endogenous opioid systems regulate cell proliferation in the developing rat brain. Brain Res1987; 412: 68–72.
18.
McLaughlinPJZagonIS. Modulation of human neuroblastoma transplanted into nude mice by endogenous opioid systems. Life Sci1987; 41: 1465–72.
19.
ZagonISRhodesREMcLaughlinPJ. Distribution of enkephalin immunoreactivity in germinative cells of developing rat cerebellum. Science1985; 227: 1049–51.
20.
ZagonISRhodesREMcLaughlinPJ. Localization of enkephalin immunoreactivity in diverse tissues and cells of the developing and adult rat. Cell Tiss Res1986; 246: 561–5.
21.
MeilandtWJYu Gui-QiuRobersonEDPalopJJWuTScearce-LevieKMuckeL. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer’s disease. J Neurosci2008; 28: 5007–17.
22.
McLaughlinPJ. Regulation of DNA synthesis of myocardial and epicardial cells in developing rat heart by [Met5]-enkephalin. Amer J Physiol1996; 271: R122–9..
23.
ZagonISWuYMcLaughlinPJ. The opioid growth factor, [Met5]-enkephalin, and the ζ (zeta) opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis. J Invest Dermatol1996; 106: 490–7..
24.
ZagonISSassaniJWKaneERMcLaughlinPJ. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor. Brain Res1997; 759: 92–102.
25.
ZagonISHytrekSDMcLaughlinPJ. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Amer J Physiol1996; 271: R511–8.
26.
ZagonISSmithJPMcLaughlinPJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol1999; 14: 577–84.
27.
McLaughlinPJZagonISSkitzkiJ. Human neuroblastoma cell growth in tissue culture is regulated by opioid growth factor. Int J Oncol1999; 14: 373–80.
28.
McLaughlinPJLevinRJZagonIS. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by the opioid growth factor. Int J Oncol1999; 14: 991–8.
29.
BisignaniGJMcLaughlinPJOrdilleSDJarowenkoMJZagonIS. Human renal cell proliferation in tissue culture is tonically inhibited by opioid growth factor. J Urol1999; 162: 2186–91.
30.
McLaughlinPJGoldenbergDParkSSConwayADonahueRNZagonIS. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) – opioid growth factor receptor (OGFr) axis. BMC Cancer2009; 9: 369–369.
31.
AvellaDMKimchiETDonahueRNTagaramHRMcLaughlinPJZagonISStaveley-O'CarrollKF. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. Amer J Physiol Regul Integr Comp Physiol2010; 298: R459–66..
32.
ZagonISPorterfieldNKMcLaughlinPJ. Opioid growth factor (OGF) – opioid growth factor receptor (OGFr) axis inhibits proliferation of triple negative breast cancer. Exp Biol Med2013, in press.
33.
ZagonISDonahueRNMcLaughlinPJ. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Amer J Physiol2009; 297: R1154–61.
34.
ZagonISMcLaughlinPJ. An opioid growth factor regulates the replication of microorganisms. Life Sci1992; 50: 1179–87.
35.
ZagonISMcLaughlinPJ. Identification of opioid peptides regulating proliferation of neurons and glia in the developing nervous system. Brain Res1991; 542: 318–23.
36.
ZagonISHurstWJMcLaughlinPJ. Identification of [Met5]-enkephalin in developing, adult, and renewing tissues by reversed-phase high-performance liquid chromatography and radioimmunoassay. Life Sci197; 61: 363–70.
37.
MosnaimADPuenteJWolfMECallaghanOHBuschRDiamondS. Studies of the in vitro human plasma degradation of methionine-enkephalin. Gen Pharmacol1988; 19: 729–3.
38.
ZagonISMcLaughlinPJ. Naltrexone modulates body and brain development in rats: a role for endogenous opioids in growth. Life Sci1984; 35: 2057–64.
39.
ZagonISMcLaughlinPJ. Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer. Life Sci1984; 35: 409–16.
40.
ZagonISMcLaughlinPJ. Opiate-antagonist induced regulation of organ development. Physiol Behav1985; 34: 507–11.
41.
ZagonISMcLaughlinPJ. Opioid antagonist (naltrexone) modulation of cerebellar development: histological and morphometric studies. J Neurosci1986; 6: 1424–32.
42.
ZagonISMcLaughlinPJ. Modulation of murine neuroblastoma in nude mice by opioid antagonists. J Natl Cancer Inst1987; 78: 141–7.
43.
ZagonISMcLaughlinPJ. Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors. Brain Res1989; 480: 16–28.
44.
ZagonISMcLaughlinPJ. Naloxone modulates body and organ growth of rats: dependency on the duration of opioid receptor blockade and stereospecificity. Pharmacol Biochem Behav1989; 33: 325–8..
45.
ZagonISMcLaughlinPJ. Opioid antagonist (naltrexone) stimulation of cell proliferation in human and animal neuroblastoma and human fibrosarcoma cells in culture. Neuroscience1990; 37: 223–6.
46.
ZagonISGoodmanSRMcLaughlinPJ. Characterization of opioid binding sites in murine neuroblastoma. Brain Res1988; 449: 80–8.
47.
ZagonISGoodmanSRMcLaughlinPJ. Characterization of zeta (ζ): a new opioid receptor involved in growth. Brain Res1989; 482: 297–305.
48.
ZagonISGoodmanSRMcLaughlinPJ. Demonstration and characterization of zeta (ζ), a growth-related opioid receptor, in a neuroblastoma cell line. Brain Res1990; 511: 181–8.
49.
ZagonISGiboDMMcLaughlinPJ. Zeta (ζ), a growth-related opioid receptor in the developing rat cerebellum: identification and characterization. Brain Res1991; 551: 28–35.
50.
ZagonISGoodmanSRMcLaughlinPJ. Zeta (ζ), the opioid growth factor receptor: identification and characterization of binding subunits. Brain Res1993; 605: 50–6.
51.
ZagonISVerderameMFAllenSMcLaughlinPJ. Cloning, sequencing, expression, and function of a cDNA encoding a receptor for the opioid growth factor, [Met5]-enkephalin. Brain Res1999; 849: 147–54.
52.
ZagonISVerderameMFAllenSSMcLaughlinPJ. Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans. Brain Res2000; 856: 75–83.
53.
ZagonISVerderameMFZimmerWEMcLaughlinPJ. Molecular characterization and distribution of the opioid growth factor receptor (OGFr) in mouse. Mol Brain Res2000; 84: 106–14.
54.
ZagonISVerderameMFMcLaughlinPJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev2002; 38: 351–76.
55.
ZagonISRuthTBLeure-duPreeAESassaniJWMcLaughlinPJ. Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res2003; 967: 37–7.
56.
ZagonISRuthTBMcLaughlinPJ. Nucleocytoplasmic distribution of opioid growth factor (OGF) and its receptor (OGFr) in tongue epithelium. Anat Rec A: Discov Mol Cell Evol Biol2005; 282: 24–37.
57.
ChengFMcLaughlinPJMF. Verderame, Zagon IS. Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Exp Biol Med2009; 234: 532–41.
58.
TannerMMGrenmanSKoulA. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res2000; 6: 1833–9.
59.
DonahueRNMcLaughlinPJZagonIS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol2009; 296: R1716–25.
60.
McLaughlinPJLevinRJZagonIS. Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. Cancer Lett2003; 199: 209–17.
61.
McLaughlinPJStackBCBraineKMRudaJDZagonIS. Opioid growth factor (OGF) inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. Int J Oncol2004; 24: 227–32.
62.
McLaughlinPJStackBCJrLevinRJFedokFZagonIS. Defects in the OGF receptor (OGFr) in human squamous cell carcinoma of the head and neck. Cancer2003; 97: 1701–10.
63.
DonahueRNZagonISMcLaughlinPJ. The opioid growth factor inhibits established ovarian cancer in nude mice and can be combined with taxol or cisplatin to enhance growth inhibition. J Cancer Ther2011; 2: 110–24.
64.
DonahueRNMcLaughlinPJZagonIS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol2011; 122: 382–8.
65.
DonahueRNMcLaughlinPJZagonIS. Overexpression of the opioid growth factor receptor (OGFr) in human ovarian cancer cells downregulates cell proliferation in vitro and inhibits tumorigenesis in mice. J Cancer Ther2011; 2: 579–94.
66.
DonahueRNMcLaughlinPJZagonIS. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer. Exp Biol Med2012; 237: 167–77.
67.
FanningJHosslerCAKestersonJPDonahueRNMcLaughlinPJZagonIS. Expression of the opioid growth factor – opioid growth factor receptor axis in human ovarian cancer. Gynecol Oncol2012; 124: 319–24.
68.
ZagonISMcLaughlinPJ. 1995. Gene-peptide relationships in the developing rat brain: The response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure. Mol Brain Res1995; 33: 111–20.
69.
DonahueRNMcLaughlinPJZagonIS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med2011; 236: 1036–50.
70.
DonahueRNMcLaughlinPJZagonIS. Low dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med2011; 236: 883–95.
71.
McLaughlinPJJaglowskiJRVerderameMFStackBCLeure-duPreeAEZagonIS. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. Int J Oncol2005; 26: 809–16.
72.
JaglowskiJRZagonISStackBCVerderameMFLeure-duPreeAEManningJDMcLaughlinPJ. Opioid growth factor enhances tumour growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol2005; 56: 97–104.
73.
ZagonISJaglowskiJRVerderameMFLeure-duPreeAESmithJPMcLaughlinPJ. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol2005; 56: 510–20.
74.
McLaughlinPJStuckiJKZagonIS. Modulation of the opioid growth factor ([Met5]-enkephalin) – opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck. Head Neck2012; 34: 513–19.
75.
HytrekSDMcLaughlinPJLangCMZagonIS. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone. Cancer Lett1996; 101: 159–64.
76.
McLaughlinPJZagonIS. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor (OGFr). Int J Oncol2006; 28: 1577–83.
77.
McLaughlinPJVerderameMFHankinsJLZagonIS. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. Int J Mol Med2007; 19: 421–8.
78.
ZagonISVerderameMFHankinsJLMcLaughlinPJ. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol2007; 30: 775–83.
79.
McLaughlinPJKreinerSMorganCRZagonIS. Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor. Int J Oncol2008; 33: 751–7.
80.
ChengFMcLaughlinPJVerderameMFZagonIS. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell2009; 20: 319–27.
81.
ChengFZagonISVerderameMFMcLaughlinPJ. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res2007; 67: 10511–18.
82.
ChengFMcLaughlinPJVerderameMFZagonIS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer2008; 7: 5–17.
83.
SmithJPConterRLBingamanSIHarveyJAMaugerDTAhmadMDemersLMStanleyWBMcLaughlinZagonIS. Treatment of advanced pancreatic cancer with opioid growth factor: Phase I. Anti Cancer Drug2004; 15: 203–9.
84.
SmithJPBingamanSIMaugerDTHarveyHADemersLMZagonIS. Opioid growth factor (OGF) improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J Clinical Trials2010; 2: 37–48.
